Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Abstract Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics. Mepolizumab, an anti-interleukin-5 monoclonal antibody, in...

Full description

Bibliographic Details
Main Authors: Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Churg–Strauss syndrome
Eosinophilic granulomatosis with polyangiitis
Intravenous immunoglobulin
Mepolizumab
Systemic vasculitis
Online Access:https://doi.org/10.1186/s13223-023-00801-7

Internet

https://doi.org/10.1186/s13223-023-00801-7

Similar Items